Ibritumomab tiuxetan is a monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin lymphoma via a conjugated radioactive isotope. Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chain of 445 amino acids each and two kappa light chains of 213 amino acids each.
Mechanism of action
The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via the production of beta particles.
Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines)
The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), allowing radiation from the attached isotope (mostly beta emission) to kill it and some nearby cells. In addition, the antibody itself may trigger cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Together, these actions eliminate B cells from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.[rx]
Indications
- Ibritumomab is used to treat relapsed or refractory, low-grade or transformed B cell non-Hodgkin’s lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adult patients who achieve a partial or complete response to first-line chemotherapy.[rx] The treatment should not be administered to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve
- For the treatment of non-Hodgkin’s lymphoma
- Follicular Non-Hodgkin’s Lymphoma
- Follicular Non-Hodgkin’s Lymphoma Refractory
- Relapsed follicular B-cell non-Hodgkin’s lymphoma
Contraindications
- decreased function of bone marrow
- increased risk of bleeding due to clotting disorder
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- pregnancy
- a patient who is producing milk and breastfeeding
- a bad infection
- significantly decreased activity of the bone marrow
- anemia
- bleeding
- pregnancy
Dosage
Strengths: 3.2 mg/2 mL
Non-Hodgkin’s Lymphoma
Day 7, 8, or 9 following initial rituximab infusion:
- Within 4 hours of rituximab, administer Y-90 ibritumomab 0.4 mCi/kg (14.8 MBq/kg) actual body weight intravenously over 10 minutes for patients with normal platelet count (Platelet count greater than 150,000/mm3).
- Maximum dose: 32 mCi (1184 MBq) Y-90 ibritumomab dose regardless of actual body weight.
- Do not treat if platelets less than 100,000/mm3
- Initiate the regimen following recovery of platelet counts to at least 150,000/mm3 at least 6 weeks, but not more than 12 weeks, following the last dose of first-line chemotherapy
Dose Adjustments
- Platelet count between 100,000/mm3 and 149,000/mm3 (in relapsed or refractory patients): Y-90 ibritumomab 0.3 mCi/kg (11.1 MBq/kg) actual body weight intravenously over 10 minutes
Administration advice:
- Administer Y-90 ibritumomab through a free-flowing intravenous line.
- Use a 0.22 micron low-protein-binding in-line filter between the syringe and the infusion port.
- After injection, flush the line with at least 10 mL normal saline.
Side Effects
The Most Common
- nausea
- vomiting
- stomach pain or swelling
- constipation
- heartburn
- loss of appetite
- headache
- anxiety
- dizziness
- difficulty falling asleep or staying asleep
- back, joint, or muscle pain
- flushing
- redness, tenderness, or an open wound in the area where the medication was injected
- redness, ulcers, or skin changes where the medicine was injected;
- easy bruising, unusual bleeding, purple or red spots under your skin;
- unusual weakness or tiredness;
- low red blood cells (anemia)–pale skin, weakness, cold hands and feet; or
- low white blood cell counts–fever, mouth sores, skin sores, sore throat, cough, trouble breathing.
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- cough or hoarseness
- coughing up blood
- difficulty with breathing or swallowing
- dizziness
- fever or chills
- headache
- increased menstrual flow or vaginal bleeding
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- lower back or side pain
- noisy breathing
- nosebleeds
- painful or difficult urination
- pale skin
- paralysis
- pinpoint red spots on the skin
- prolonged bleeding from cuts
- red or dark brown urine
- red stools
- shortness of breath
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swollen glands
- tightness in the chest
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- wheezing
Rare
- Bloody nose that does not stop after pinching the nose together and holding it for 5 to 10 minutes
- bluish lips or skin
- chest pain or discomfort
- confusion
- diarrhea
- fainting
- fast heartbeat
- hives
- itching
- lightheadedness
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- rapid, shallow breathing
- skin rash
- small red or purple spots on the skin
- unusual vaginal bleeding
- vomiting blood or material that looks like coffee grounds
- Agitation
- anxiety
- back pain
- bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, or warmth at the injection site
- blurred vision
- coma
- drowsiness
- fast, pounding, or irregular heartbeat or pulse
- hallucinations
- inability to speak
- irritability
- mood or mental changes
- nausea
- redness of the skin
- seizures
- severe headache
- slurred speech
- stiff neck
- temporary blindness
- vomiting
- weakness in the arm or leg on one side of the body, sudden and severe
- welts
- Blistering, peeling, or loosening of the skin
- cracks in the skin
- joint or muscle pain
- loss of heat from the body
- red skin lesions, often with a purple center
- red, irritated eyes
- red, swollen skin
- scaly skin
- skin blisters
Drug Interactions
| Abatacept | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan. |
| Acetylsalicylic acid | The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan. |
| Adenovirus | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibritumomab tiuxetan. |
| Aducanumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aducanumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan. |
| Alefacept | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab. |
| Alirocumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alirocumab. |
| Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ibritumomab tiuxetan. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan. |
| Altretamine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine. |
| Amivantamab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amivantamab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine. |
| Anagrelide | The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Ibritumomab tiuxetan. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan. |
| Ansuvimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ansuvimab. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibritumomab tiuxetan. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse). |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ibritumomab tiuxetan. |
| Antithrombin III | The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit). |
| Apixaban | The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan. |
| Apremilast | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apremilast. |
| Ardeparin | The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Ibritumomab tiuxetan. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide. |
| Asfotase alfa | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asfotase alfa. |
| ACOVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Atezolizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab. |
| Atoltivimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atoltivimab. |
| Avelumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine. |
| Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibritumomab tiuxetan. |
| Bacillusantigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ibritumomab tiuxetan. |
| Bacillus antigen | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibritumomab tiuxetan. |
| Bamlanivimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bamlanivimab. |
| Baricitinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Ibritumomab tiuxetan. |
| Beclomethasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate. |
| Belantamab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin. |
| Belatacept | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Ibritumomab tiuxetan. |
| Bendamustine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bendamustine. |
| Bendroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibritumomab tiuxetan. |
| Benralizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab. |
| Benzthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibritumomab tiuxetan. |
| Besilesomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Besilesomab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone. |
| Betrixaban | The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene. |
| Bezlotoxumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bezlotoxumab. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan. |
| Bleomycin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blinatumomab. |
| Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Bortezomib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib. |
| Bosutinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib. |
| Brentuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brentuximab vedotin. |
| Brodalumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab. |
| Brolucizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab. |
| Budesonide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide. |
| Burosumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab. |
| Busulfan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel. |
| Canakinumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Canakinumab. |
| Cangrelor | The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan. |
| Capecitabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capecitabine. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine. |
| Casirivimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Casirivimab. |
| Catumaxomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab. |
| Cemiplimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Certolizumab pegol. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol. |
| Chlorothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibritumomab tiuxetan. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide. |
| Cilgavimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cilgavimab. |
| Cilostazol | The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan. |
| Cisplatin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin. |
| Cladribine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine. |
| Clobetasol | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine. |
| Clopidogrel | The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan. |
| Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Clozapine | The risk or severity of neutropenia can be increased when Ibritumomab tiuxetan is combined with Clozapine. |
| Coestrogens | Conjugated estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Corticotropin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan. |
| Cyclopenthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibritumomab tiuxetan. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide. |
| Cyclosporine | Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibritumomab tiuxetan. |
| Cytarabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine. |
| Dabigatran | The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan. |
| Dabigatran | The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Ibritumomab tiuxetan. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Ibritumomab tiuxetan. |
| Daratumumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab. |
| Dasatinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine. |
| Defibrotide | The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan. |
| Deflazacort | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deflazacort. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Ibritumomab tiuxetan. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Desoximetasone. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deucravacitinib. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane. |
| Dextran | The risk or severity of bleeding can be increased when Dextran is combined with Ibritumomab tiuxetan. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Difluocortolone. |
| Digoxin | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dimethyl fumarate. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab. |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan. |
| Diroximel f | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Diroximel fumarate. |
| Docetaxel | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Docetaxel. |
| Dostarlimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dostarlimab. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan. |
| Dulaglutide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide. |
| Dupilumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab. |
| Durvalumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab. |
| Ebola Zaire | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Eculizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Ibritumomab tiuxetan. |
| Edoxaban | The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan. |
| Efalizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab. |
| Eflapegrastim | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eflapegrastim. |
| Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa. |
| Elotuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab. |
| Emapalumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab. |
| Emicizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emicizumab. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Ibritumomab tiuxetan. |
| Epirubicin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin. |
| Epoprostenol | The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan. |
| Eptifibatide | The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan. |
| Eptinezumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab. |
| Erenumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Erenumab. |
| Eribulin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin. |
| Es estrogens | Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estetrol | Estetrol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estradiol | Estradiol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estramustine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine. |
| Estriol | Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estrone | Estrone may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Etoposide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide. |
| Everolimus | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Everolimus. |
| Evolocumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Ibritumomab tiuxetan. |
| Fanolesomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fanolesomab. |
| Filgotinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Filgotinib. |
| Fingolimod | Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod. |
| Floxuridine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone. |
| Fluindione | The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan. |
| Flunisolide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide. |
| Fluocinolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinonide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorometholone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil. |
| Flupentixol | The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ibritumomab tiuxetan. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone. |
| Fluticasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone. |
| Fluticasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone furoate. |
| Fluticasone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate. |
| Fondaparinux | The risk or severity of bleeding can be increased when Fondaparinux is combined with Ibritumomab tiuxetan. |
| Fremanezumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fremanezumab. |
| Galcanezumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gallium nitrate. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine. |
| Gemtuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan. |
| Glatiramer | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glatiramer. |
| Golimumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab. |
| Guselkumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab. |
| Ipilimumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab. |
| Irinotecan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan. |
| Isatuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Isatuximab. |
| Ixabepilone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab. |
| JaCOVID-19 Vaccine | The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Jap encephalitis | The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Lanadelumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lanadelumab. |
| Leflunomide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan. |
| Linezolid | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid. |
| Lipegfilgrastim | Ibritumomab tiuxetan may increase the myelosuppressive activities of Lipegfilgrastim. |
| Lomustine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lomustine. |
| Loncastuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Loncastuximab tesirine. |
| Lopinavir | The serum concentration of Ibritumomab tiuxetan can be increased when it is combined with Lopinavir. |
| Maftivimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Maftivimab. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Ibritumomab tiuxetan. |
| Margetuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab. |
| Measles virus | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Ibritumomab tiuxetan. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine. |
| Melphalan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mepolizumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine. |
| Mestranol | Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Methimazole | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone. |
| Mirvetuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirvetuximab Soravtansine. |
| Mitomycin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone. |
| MCOVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Modified vaccinia | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibritumomab tiuxetan. |
| Mogamulizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab. |
| Mometasone furoate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate. |
| Monomethyl | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Monomethyl fumarate. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mosunetuzumab. |
| Mumps virus strain | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Ibritumomab tiuxetan. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan. |
| Mycophenolate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid. |
| Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Ibritumomab tiuxetan. |
| Natalizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab. |
| Necitumumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab. |
| Nelarabine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nelarabine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nilotinib. |
| Nimesulide | The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan. |
| Nivolumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ibritumomab tiuxetan. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Ibritumomab tiuxetan. |
| Odesivimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Odesivimab. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab. |
| Olaparib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib. |
| Olaratumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin. |
| Ozanimod | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paclitaxel. |
| Palbociclib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan. |
| Palivizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab. |
| Panobinostat | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat. |
| Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Ibritumomab tiuxetan. |
| Pazopanib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pazopanib. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pegcetacoplan. |
| Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan. |
| Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan. |
| Peginterferon | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a. |
| Pembrolizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pembrolizumab. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed. |
| Penicillamine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine. |
| Pentosan | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ibritumomab tiuxetan. |
| Pentostatin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin. |
| Pentoxifylline | The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Pertuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pertuzumab. |
| Phenindione | The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirfenidone. |
| Polatuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin. |
| Polyestradiol | Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Polythiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibritumomab tiuxetan. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponesimod. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate. |
| Prasugrel | The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan. |
| Prednisolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil. |
| Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Ibritumomab tiuxetan. |
| Protein S | The risk or severity of bleeding can be increased when Protein S human is combined with Ibritumomab tiuxetan. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ibritumomab tiuxetan. |
| Rabies antigen, A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan. |
| Rabies antigen, B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibritumomab tiuxetan. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ramucirumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ravulizumab. |
| Raxibacumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab. |
| Reslizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab. |
| Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan. |
| Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Ibritumomab tiuxetan. |
| Rilonacept | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept. |
| Risankizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Risankizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan. |
| Rivaroxaban | The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan. |
| Romosozumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Romosozumab. |
| Ropeginter | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ropeginterferon alfa-2b. |
| Rotavirus vacci | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Rubella virus | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib. |
| Sacituzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan. |
| Sarilumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Satralizumab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab. |
| Siltuximab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab. |
| Siponimod | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan. |
| Sirolimus | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus. |
| Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ibritumomab tiuxetan. |
| Sodium citrate | The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan. |
| Sorafenib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib. |
| Sotrovimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotrovimab. |
| Spesolimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Spesolimab. |
| Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan. |
| Streptozocin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin. |
| Sulesomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulesomab. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ibritumomab tiuxetan. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine. |
| Sulfinpyrazone | The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan. |
| Sulodexide | The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan. |
| Sunitinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sunitinib. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sutimlimab. |
| SEstrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| S Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Ibritumomab tiuxetan. |
| Tafasitamab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab. |
| Tedizolid phosphate | The risk or severity of myelosuppression can be increased when Ibritumomab tiuxetan is combined with Tedizolid phosphate. |
| Temozolomide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temsirolimus. |
| Tenecteplase | The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan. |
| Teniposide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide. |
| Teplizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide. |
| Tetanus immune | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetanus immune globulin, human. |
| Tezepelumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab. |
| Thalidomide | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide. |
| Thiotepa | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa. |
| Tibolone | Tibolone may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Ticagrelor | The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan. |
| Tick encephalitis | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Ticlopidine | The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan. |
| Tildrakizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab. |
| Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Ibritumomab tiuxetan. |
| Tioguanine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine. |
| Tirofiban | The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan. |
| Tisotumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tisotumab vedotin. |
| Tixagevimab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixagevimab. |
| Tixocortol | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixocortol. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tocilizumab. |
| Tofacitinib | Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib. |
| Topotecan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab. |
| Trabectedin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin. |
| Tralokinumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab deruxtecan. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab emtansine. |
| Tremelimumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tremelimumab. |
| Tretinoin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone. |
| Trichlormethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibritumomab tiuxetan. |
| Trifluridine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine. |
| Triflusal | The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan. |
| Trilostane | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibritumomab tiuxetan. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibritumomab tiuxetan. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Upadacitinib. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ustekinumab. |
| Varicella zoster | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ibritumomab tiuxetan. |
| Varicella | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ibritumomab tiuxetan. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vedolizumab. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ibritumomab tiuxetan. |
| Vilanterol | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol. |
| Vinblastine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine. |
| Vindesine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine. |
| Voclosporin | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Voclosporin. |
| Vorapaxar | The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan. |
| Vorinostat | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vorinostat. |
| Warfarin | The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan. |
| Ximelagatran | The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan. |
| Yel fever vaccine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ibritumomab tiuxetan. |
| Zidovudine | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine. |
Pregnancy and Lactation
US FDA pregnancy category: Unassigned
Pregnancy
This drug may cause fetal harm when administered to a pregnant woman. Potential fetal risk should be considered and informed if pregnancy occurs while receiving treatment with this drug. Encourage male and female patients to use adequate methods of contraception during and for a minimum of 12 months following treatment. Pregnancy testing in females should be conducted prior to treatment.
Lactation
- Use should be avoided during treatment, and for 6 months after the last dose. According to some authorities, the use during lactation is contraindicated.
- Excreted into human milk: Unknown
- Excreted into animal milk: Unknown
- There is no information regarding this drug on its presence in human milk, its effects on a breastfed infant, or its effects on milk production.
How should this medicine be used?
Ibritumomab injection comes as a liquid to be injected into a vein over 10 minutes by a doctor who has been trained to treat patients with radioactive medication. It is given as part of a specific cancer treatment regimen. On the first day of the treatment regimen, a dose of rituximab is given and the first dose of ibritumomab injection is given no more than 4 hours afterward. Imaging scans to see how ibritumomab injection has spread through the body are performed 48 to 72 hours after the dose of ibritumomab injection is given. Additional scans may be performed if needed during the next several days. If the results of the scan(s) show that the ibritumomab injection has spread through the body as expected, the second dose of rituximab and a second dose of ibritumomab injection will be given 7 to 9 days after the first doses were given.
What special precautions should I follow?
Before receiving an ibritumomab injection,
- tell your doctor and pharmacist if you are allergic to ibritumomab, any of the medications mentioned in the IMPORTANT WARNING section, any other medications, or any of the ingredients in ibritumomab injection. Ask your doctor or pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had any medical condition.
- tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are receiving ibritumomab. If you are female, you will need to take a pregnancy test before starting treatment and use birth control to prevent pregnancy during your treatment and for 12 months after your final dose. If you are a male with a female partner, use birth control to prevent pregnancy during your treatment and for 12 months after your final dose. If you or your partner become pregnant while receiving ibritumomab injection, call your doctor immediately. Ibritumomab injection may harm the fetus.
- tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while receiving ibritumomab and for 6 months after your final dose.
- you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving ibritumomab.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you have received ibritumomab injection.
- do not have any vaccinations during treatment and for 12 months after your final dose without first talking to your doctor.
- you should know that the radioactivity in the second dose of ibritumomab injection may be present in your body fluids for up to a week after you receive the dose. To prevent the radioactivity from spreading to people who are in close contact with you, you should be sure to wash your hands thoroughly after using the bathroom, use a condom every time you have sexual intercourse, and avoid deep kissing. Follow these precautions during your treatment and for 7 days after you receive your second dose of ibritumomab injection.
- you should know that ibritumomab injection contains albumin (a product that is made from live donor blood). Although there is an extremely small chance that viruses may be spread through the blood, no cases of viral diseases from this product have been reported.
- you should know that if you receive ibritumomab injection, your body may develop antibodies (substances in the blood that help the immune system recognize and attack foreign substances) to murine proteins. If you develop these antibodies, you may have an allergic reaction when you take medications made from murine proteins, or these medications might not work well for you.After your treatment with ibritumomab injection, be sure to tell all of your doctors that you have been treated with ibritumomab injection.
References
